Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 6/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 6/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 3/20 | 1.00 |
| ▸ | GRIA2 | P42262 | 16/20 | 0.71 |
| ▸ | CYP2C9 | P11712 | 9/20 | 0.71 |
| ▸ | GAA | P10253 | 1/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3139190 | 0.87 | CYP1A2 (0.78) | CYP1A2CYP2D6CYP2C19GRIA2CYP2C9 | |
| SCHEMBL3140870 | 0.85 | GRIA2 (0.76) | CYP1A2CYP2D6CYP2C19GRIA2CYP2C9 | |
| SCHEMBL3136113 | 0.83 | GRIA2 (1.00) | CYP1A2CYP2D6CYP2C19GRIA2CYP2C9 | |
| SCHEMBL3143438 | 0.83 | GRIA2 (0.76) | CYP1A2CYP2D6CYP2C19GRIA2CYP2C9 | |
| SCHEMBL3139210 | 0.82 | GRIA2 (0.78) | CYP1A2CYP2D6CYP2C19GRIA2CYP2C9 | |
| SCHEMBL3128748 | 0.82 | GRIA2 (0.79) | CYP1A2CYP2D6CYP2C19GRIA2CYP2C9 | |
| SCHEMBL3132274 | 0.81 | GRIA2 (0.81) | CYP1A2CYP2D6CYP2C19GRIA2CYP2C9 | |
| SCHEMBL3144380 | 0.81 | GRIA2 (1.00) | CYP1A2CYP2D6CYP2C19GRIA2CYP2C9 | |
| SCHEMBL8230950 | 0.81 | GRIA2 (0.77) | CYP1A2CYP2D6CYP2C19GRIA2CYP2C9 | |
| SCHEMBL3143860 | 0.81 | GRIA2 (1.00) | CYP1A2CYP2D6CYP2C19GRIA2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7642256-B2 | Compounds which potentiate AMPA receptor and uses thereof in medicine | GLAXO GROUP LIMITED (GB) | 2010-01-05 | — | — | US | disclosed |
| US-7642256-B2 | Compounds which potentiate AMPA receptor and uses thereof in medicine | GLAXO GROUP LIMITED (GB) | 2010-01-05 | — | — | US | disclosed |
| US-7642256-B2 | Compounds which potentiate AMPA receptor and uses thereof in medicine | GLAXO GROUP LIMITED (GB) | 2010-01-05 | — | — | US | disclosed |
| US-7566735-B2 | Compounds which potentiate AMPA receptor and uses thereof in medicine | GLAXO GROUP LIMITED (GB) | 2009-07-28 | — | — | US | disclosed |
| US-7566735-B2 | Compounds which potentiate AMPA receptor and uses thereof in medicine | GLAXO GROUP LIMITED (GB) | 2009-07-28 | — | — | US | disclosed |
| US-7566735-B2 | Compounds which potentiate AMPA receptor and uses thereof in medicine | GLAXO GROUP LIMITED (GB) | 2009-07-28 | — | — | US | disclosed |
| US-20090118280-A1 | Compounds Which Potentiate AMPA Receptor and Uses Thereof in Medicine | HARRISON STEPHEN | 2009-05-07 | — | — | US | disclosed |
| US-20090118280-A1 | Compounds Which Potentiate AMPA Receptor and Uses Thereof in Medicine | HARRISON STEPHEN | 2009-05-07 | — | — | US | disclosed |
| US-20090118280-A1 | Compounds Which Potentiate AMPA Receptor and Uses Thereof in Medicine | HARRISON STEPHEN | 2009-05-07 | — | — | US | disclosed |
| US-20080139472-A1 | UPREGULATING BDNF LEVELS TO MITIGATE MENTAL RETARDATION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2008-06-12 | — | — | US | disclosed |
| US-20080045532-A1 | Compounds which potentiate AMPA receptor and uses thereof in medicine | GLAXO GROUP LIMITED (GB) | 2008-02-21 | — | — | US | disclosed |
| US-20080045532-A1 | Compounds which potentiate AMPA receptor and uses thereof in medicine | GLAXO GROUP LIMITED (GB) | 2008-02-21 | — | — | US | disclosed |
| US-20080045532-A1 | Compounds which potentiate AMPA receptor and uses thereof in medicine | GLAXO GROUP LIMITED (GB) | 2008-02-21 | — | — | US | disclosed |
| WO-2007107539-A1 | COMPOUNDS WHICH POTENTIATE AMPA RECEPTOR AND USES THEREOF IN MEDICINE | GLAXO GROUP LIMITED (GB) | 2007-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118280-A1 | Compounds Which Potentiate AMPA Receptor and Uses Thereof in Medicine | GRIN1, GRM2, GRM1 | CYP1A2 2601/4885CYP2D6 3213/4885CYP2C19 2773/4885 |
| US-20080139472-A1 | UPREGULATING BDNF LEVELS TO MITIGATE MENTAL RETARDATION | BDNF, MECP2, NTRK2 | CYP1A2 4876/4885CYP2D6 4872/4885CYP2C19 4863/4885 |
| US-20080045532-A1 | Compounds which potentiate AMPA receptor and uses thereof in medicine | GRIN1, GRM2, GRM1 | CYP1A2 2601/4885CYP2D6 3213/4885CYP2C19 2773/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.